Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

Launched by UNIVERSITY OF COLORADO, DENVER · Aug 25, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how certain blood tests, called thromboelastography (TEG), can help doctors understand the severity of cancers in the liver, pancreas, esophagus, colon, and lungs. The researchers believe that these tests might indicate how advanced the cancer is, the chances of it coming back after treatment, and the risk of complications during and after surgery. They are also looking to see if there are specific signs in the cancer tissue that link to any unusual findings in these blood tests, which could help identify patients with more aggressive forms of cancer.

To be eligible for the study, participants must be adults aged 18 and older who have recently been diagnosed with one of the cancers being studied. Unfortunately, those who are under 18, pregnant, or unable to provide consent cannot participate. Participants in this trial will undergo the TEG tests before and after their surgery, which will help researchers gather important information about the relationship between blood test results and cancer outcomes. This study aims to improve understanding of cancer and may help in finding better ways to manage it in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study
• • 18 Years and older
• Exclusion Criteria:
• • Under 18 years old
• • prisoners
• • those unable to provide informed consent
• • pregnant women
• • and those undergoing emergent or urgent operative intervention at the time of diagnosis